Merck & Company Inc (MRK)vsBio-Techne Corp (TECH)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
TECH
Bio-Techne Corp
$72.12
+0.06%
HEALTHCARE · Cap: $11.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5379% more annual revenue ($66.57B vs $1.22B). TECH leads profitability with a 15.0% profit margin vs 4.8%. TECH appears more attractively valued with a PEG of 2.11. TECH earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold36
out of 100
Grade: F
TECH
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+67.8%
Fair Value
$197.11
Current Price
$72.12
$124.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Earnings expanding 128.6% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 27.9%
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Expensive relative to growth rate
1.3% revenue growth
ROE of 5.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : TECH
The strongest argument for TECH centers on EPS Growth, Altman Z-Score, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : TECH
The primary concerns for TECH are PEG Ratio, Revenue Growth, Return on Equity. A P/E of 62.3x leaves little room for execution misses.
Key Dynamics to Monitor
TECH carries more volatility with a beta of 1.27 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TECH scores higher overall (54/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Bio-Techne Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?